| NCT ID | NCT00378924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Cardiovascular Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2003-12 |
| Primary Completion | 2030-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,000 participants in total. It began in 2003-12 with a primary completion date of 2030-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized/Planned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers. Once the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help us to understand how these diseases can be treated more effectively. By collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.
Eligibility Criteria
Inclusion Criteria: 1. All hospital and clinic participants aged 18 years and older 2. Participants with and without active or presumed cardiovascular disease including but not limited to: 1. Coronary Artery Disease 2. Heart Failure and Cardiomyopathies 3. Peripheral Vascular Disease 4. Valve disease 5. Adult Congenital Heart disease 6. Electrophysiological Disorders 3. Any individual aged 18 and above in satisfactory physical health and able to tolerate a blood draw or buccal swab. Exclusion Criteria: 1. Significant Documented Anemia (Hemoglobin \<8 g/dL) 2. Blood transfusions within past 3 weeks 3. Enrollment against doctor recommendation 4. Participant not able to provide consent including but not limited to: 1. Intubated and critically unwell participants 2. Dementia 3. Alzheimer's disease 4. Moderate to severe alcohol or drug abuse 5. Against religious beliefs (e.g. Jehovah's witness)
Contact & Investigator
Arshed A Quyyumi, MD
PRINCIPAL INVESTIGATOR
Emory School Of Medicine
Frequently Asked Questions
Who can join the NCT00378924 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00378924 currently recruiting?
Yes, NCT00378924 is actively recruiting participants. Contact the research team at ayman.tahhan@emory.edu for enrollment information.
Where is the NCT00378924 trial being conducted?
This trial is being conducted at Atlanta, United States.
Who is sponsoring the NCT00378924 clinical trial?
NCT00378924 is sponsored by Emory University. The principal investigator is Arshed A Quyyumi, MD at Emory School Of Medicine. The trial plans to enroll 12,000 participants.